HC Wainwright Forecasts Higher Earnings for Cocrystal Pharma

Cocrystal Pharma, Inc. (NASDAQ:COCP) – Research analysts at HC Wainwright upped their FY2024 EPS estimates for shares of Cocrystal Pharma in a report issued on Wednesday, January 22nd. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($1.87) per share for the year, up from their previous estimate of ($2.03). HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($1.91) per share. HC Wainwright also issued estimates for Cocrystal Pharma’s Q4 2024 earnings at ($0.47) EPS, Q1 2025 earnings at ($0.54) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.28) EPS and FY2025 earnings at ($1.50) EPS.

Cocrystal Pharma Price Performance

COCP opened at $2.09 on Friday. The company’s 50 day simple moving average is $2.16 and its two-hundred day simple moving average is $1.99. The firm has a market capitalization of $21.26 million, a price-to-earnings ratio of -1.13 and a beta of 1.53. Cocrystal Pharma has a 1-year low of $1.33 and a 1-year high of $3.26.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.